Sally Arai, Other is a Hematology / Oncology Specialist - Hematologist (Blood) practicing in Stanford, CA
She has not yet shared a personalized biography with Doctor.com.
| University | Degree | Focus | Graduated |
|---|---|---|---|
| Geisel School of Medicine at Dartmouth | Medical Degree | 1991 |
| Institution | Focus | Year |
|---|---|---|
| Internship - Strong Memorial Hospital | 1993 | |
| Residency - Strong Memorial Hospital | 1995 | |
| Residency - Icahn School of Medicine at Mount Sinai Program A | Not Specified | |
| Fellowship - Mount Sinai Medical Center | 1998 |
| Certification | Cert. Body | Year |
|---|---|---|
| Internal medicine | Internal Medicine | Not Specified |
| Position | Organization | Time |
|---|---|---|
| Assistant Professor of Medicine (Blood and Marrow Transplantation) | the Stanford University Medical Center | Present |
| Publication | Publisher | Title | Published |
|---|---|---|---|
| Other Publication | BRITISH JOURL OF HAEMATOLOGY | The prognostic value of diagnosing concurrent multiple myeloma | 2013 |
| Other Publication | PROCEEDINGS OF THE TIOL ACADEMY OF SCIENCES OF THE UNITED STATES OF AM | H-Y antigen-binding B cells develop in male recipients of female hematopoietic cells | 2013 |
| Other Publication | JOURL OF HEART AND LUNG TRANSPLANTATION | Heart transplantation and cardiac amyloidosis: Approach to screening and novel magement strategies | 2012 |
| Other Publication | BONE MARROW TRANSPLANTATION | Long-term outcomes in patients with high | 2011 |
| Other Publication | BRITISH JOURL OF HAEMATOLOGY | Complete donor T-cell engraftment 30 days after allogeneic transplantation predicts molecular | 2010 |
| Other Publication | CYTOTHERAPY | Infusion of the allogeneic cell line NK-92 in patients with advanced rel cell cancer or melanoma | 2008 |
| Other Publication | JOURL OF CLINICAL ONCOLOGY | A cost-effectiveness alysis of adjuvant trastuzumab regimens in early HER2 | 2007 |
| Other Publication | Expert Opin Biol Ther | tural killer cells: can they be useful as adoptive immunotherapy for cancer? | 2005 |
| Other Publication | The Hematology Jourl | von Willebrand factor | 2001 |
| Other Publication | BRITISH JOURNAL OF HAEMATOLOGY | The prognostic value of diagnosing concurrent multiple myeloma | 2013 |
| Other Publication | PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES O | H-Y antigen-binding B cells develop in male recipients of female hematopoietic cells | 2013 |
| Other Publication | BLOOD | Prophylactic rituximab after allogeneic transplantation decreases B | 2012 |
| Other Publication | BONE MARROW TRANSPLANTATION | Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative | 2012 |
| Other Publication | JOURNAL OF HEART AND LUNG TRANSPLANTATION | Heart transplantation and cardiac amyloidosis | 2012 |
| Other Publication | BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | Adoptive Immunotherapy with Cytokine | 2011 |
| Other Publication | BLOOD | A phase 1 study of imatinib for corticosteroid-dependent | 2011 |
| Other Publication | BLOOD | Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH | 2011 |
| Other Publication | BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | Early CMV Viremia Is Associated with Impaired Viral Control following Nonmyeloablative | 2011 |
| Other Publication | BONE MARROW TRANSPLANTATION | Long-term outcomes in patients with high | 2011 |
| Other Publication | BRITISH JOURNAL OF HAEMATOLOGY | Complete donor T-cell engraftment 30 days after allogeneic transplantation predicts molecular | 2010 |
| Other Publication | BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | Phase I/II Trial of GN-BVC, | 2010 |
| Other Publication | EXPERT OPINION ON BIOLOGICAL THERAPY | Rituximab in hematopoietic cell transplantation | 2010 |
| Other Publication | BLOOD | TLI and ATG conditioning with low risk of graft-versus | 2009 |
| Other Publication | CYTOTHERAPY | Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma | 2008 |
| Other Publication | JOURNAL OF CLINICAL ONCOLOGY | A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2 | 2007 |
| Other Publication | Expert Opin Biol Ther | Natural killer cells: can they be useful as adoptive immunotherapy for cancer? | 2005 |
| Other Publication | Blood | Association of Foxp3 regulatory gene expression and graft-versus-host disease | 2004 |
| Other Publication | Biol Blood Marrow Transplant | Poor outcome in steroid refractory GVHD with ATG treatment | 2002 |
| Other Publication | The Hematology Journal | von Willebrand factor | 2001 |
Sally Arai, Other has not yet indicated the hospitals that she is affiliated with.
Years In Practice: 27 (started in 1998)
Accepts New Patients: Yes
Sally Arai, Other has not yet listed the medications that she commonly prescribes.
Sally Arai, Other has not yet added any information about her practice's billing policies and payment options.
